Fig. 2. Impact of mepolizumab on biomarkers of eosinophilic inflammation. (A) Reduction in blood eosinophils during mepolizumab treatment. (B) Decreased levels of serum ECP (left panel) and EDN (right panel) during therapy. Values with symbols refer to comparisons with baseline; values with lines and symbols refer to comparisons with 1 month of therapy.

ECP, eosinophil cationic protein; EDN, eosinophil derived neurotoxin.

^*P < .001, ^†P < 0.01, ^‡P < 0.05.